Table 1.
Baseline Characteristics of Study Participants
| Characteristic | Total PROBeX Cohort (n = 195) | Bedaquiline Genetic Analysis Group (n = 140) | Clofazimine Genetic Analysis Group (n = 136) |
|---|---|---|---|
| Age, median (IQR), y | 33 (28−42) | 33 (27–41) | 33 (27–42) |
| Female sex, no. (%) | 111 (57) | 71 (51) | 71 (51) |
| Race, no. (%) | |||
| Black | 160 (82) | 112 (80) | 106 (78) |
| Mixed race | 33 (17) | 26 (19) | 28 (21) |
| White | 2 (1) | 2 (1) | 2 (1) |
| BMI, median (IQR)a | 20 (18–23) | 20 (18–23) | 20 (18–23) |
| HIV positive, no. (%) | 123 (63) | 82 (59) | 80 (59) |
Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; IQR, interquartile range; PROBeX, Pharmacokinetics, Resistance, and Outcomes of Bedaquiline in MDR- and XDR-TB.
BMI calculated as weight in kilograms divided by height in meters squared.